Sava raises $36.0M Series B (United Kingdom, Oct 2026)
Reach the investors backing rounds like this
Backed by Ascensia, PHC Holdings · verified emails and LinkedIn on Datapile
Ascensia leads $36M Series B in Sava to replace fingerstick glucose testing - Tech Funding News
Sava is developing a sensor technology aimed at replacing fingerstick glucose testing. The company has secured $36 million in Series B funding, led by Ascensia, to support the commercialization and distribution of its products in Europe. Their goal is to obtain CE approval for insulin dosing without fingerstick checks within 18-24 months.
Ascensia leads $36M Series B in Sava to replace fingerstick glucose testing Tech Funding News
| Oct 09, 2026 | Sava Technologies | $36.0M | Series B | United Kingdom |
| Oct 08, 2026 | IMMIX | $3.5M | — | United Kingdom |
| Oct 03, 2026 | Extend Robotics | $3.3M | Seed | United Kingdom |
| Oct 01, 2026 | Metaview | $60.0M | Series C | United Kingdom |
14,750 investors back startups in United Kingdom
You just read who funded Sava. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.